Highlights

MyBiotics have reached the pre-clinical stage with two of its products following animal validation of the technologies. Drug and clinical programs are in progress while other capabilities and potential markets are becoming more relevant. We are seeking collaboration and strategic partnerships also in the non-pharmaceutical and out of our existing clinical plans. 

The proven advantages in formulation and production open new market opportunities in various products and applications and can be translated from science to preclinical or product within months. Food and supplements, skin and dermatology formulations have been developed and improved to allow introduction of new and existing bacteria to overcome dysbiosis and cure diseases related to these conditions.